LUX BIOSCIENCES TO APPEAL EMA DECISION ON LUVENIQ™

EDMONTON, June 24, 2011 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) today announced that its partner, Lux Biosciences, Inc. will appeal the European Medicines Agency's (EMA) decision not to approve Luveniq™ (voclosporin) as a treatment for noninfectious uveitis involving the intermediate or posterior segments of the eye.  The members of the Committee for Medicinal Products for Human Use (CHMP - the EMA body that prepares the opinion), adopted a negative opinion recommending that marketing authorization should not be granted for Luveniq™.

Lux remains fully committed to the potential of Luveniq™ in the treatment of noninfectious uveitis.  Lux believes that it has sufficient data to request a re-assessment of the application, and has 15 days in which to file the appeal.

In the U.S. Lux continues to address the U.S. Food and Drug Administration's (FDA) request for additional clinical information and commenced an additional pivotal trial of Luveniq™ in February of this year.

In 2006, Isotechnika granted Lux worldwide rights to develop and commercialize voclosporin for ophthalmic diseases.  In return, Isotechnika will receive development milestones payments, as well as royalties on net sales.  Voclosporin (branded as Luveniq™ by Lux) has received Orphan Drug designation in both Europe and the US for the treatment of noninfectious uveitis.

About Isotechnika Pharma Inc.

Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics designed to offer key safety advantages over currently available treatments.  Its lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at the estimated $3.0 billion market for this class of immunosuppressants.

Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at www.isotechnika.com or www.SEDAR.com.

We seek safe harbor.

 

SOURCE Isotechnika Pharma Inc.

For further information:

Dr. Robert Foster 
President & CEO
780-487-1600 (247)
rfoster@isotechnika.com












Dr. Launa Aspeslet
Chief Operating Officer
780-487-1600 (225)
laspeslet@isotechnika.com

 

Organization Profile

Isotechnika Pharma Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890